AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps. Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard therapy. The approval by the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!